BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today a ...
The net proceeds from these warrant exercises, along with the net proceeds of approximately $141 million from the recent public offering that closed on February 20, 2026, and its existing cash and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results